PI3K/Akt/mTOR pathway as a target for cancer therapy
- PMID: 16096426
- DOI: 10.1097/01.cad.0000173476.67239.3b
PI3K/Akt/mTOR pathway as a target for cancer therapy
Abstract
The PI3K/Akt/mTOR pathway regulates several normal cellular functions that are also critical for tumorigenesis, including cellular proliferation, growth, survival and mobility. Components of this pathway are frequently abnormal in a variety of tumors, making them an attractive target for anti-cancer therapy. Inhibition of mTOR in patients with cancer became more feasible after the development of rapamycin analogs with improved pharmacologic properties. The promising activity of these agents in early clinical trials has led to the development of ongoing phase III trials in renal cell carcinoma and breast cancer. Future studies are needed to identify the patients most likely to benefit from this form of therapy, and to define its role in combination with chemotherapy, hormones and growth factor inhibitors.
Similar articles
-
New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.Expert Opin Investig Drugs. 2010 Aug;19(8):919-30. doi: 10.1517/13543784.2010.499121. Expert Opin Investig Drugs. 2010. PMID: 20569080 Review.
-
Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.Cancer Treat Rev. 2014 Sep;40(8):980-9. doi: 10.1016/j.ctrv.2014.06.006. Epub 2014 Jul 3. Cancer Treat Rev. 2014. PMID: 25037117 Review.
-
Current status and challenges associated with targeting mTOR for cancer therapy.BioDrugs. 2009;23(2):77-91. doi: 10.2165/00063030-200923020-00002. BioDrugs. 2009. PMID: 19489650 Review.
-
mTOR inhibitors in the treatment of cancer.Expert Opin Investig Drugs. 2008 Nov;17(11):1717-34. doi: 10.1517/13543784.17.11.1717. Expert Opin Investig Drugs. 2008. PMID: 18922108 Review.
-
[PI3K-AKT-mTOR pathway inhibitors].Bull Cancer. 2006 Jan;93(1):19-26. Bull Cancer. 2006. PMID: 16455502 Review. French.
Cited by
-
Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer.Exp Mol Med. 2024 May;56(5):1137-1149. doi: 10.1038/s12276-024-01221-2. Epub 2024 May 1. Exp Mol Med. 2024. PMID: 38689087 Free PMC article.
-
Personalized Medicine in Brain Gliomas: Targeted Therapy, Patient-Derived Tumor Models (Review).Sovrem Tekhnologii Med. 2023;15(3):61-71. doi: 10.17691/stm2023.15.3.07. Epub 2023 May 28. Sovrem Tekhnologii Med. 2023. PMID: 38435477 Free PMC article. Review.
-
Pectolinarigenin regulates the tumor-associated proteins in AGS-xenograft BALB/c nude mice.Mol Biol Rep. 2024 Feb 16;51(1):305. doi: 10.1007/s11033-023-09046-4. Mol Biol Rep. 2024. PMID: 38361124 Free PMC article.
-
The oncogenic mechanisms of the Janus kinase-signal transducer and activator of transcription pathway in digestive tract tumors.Cell Commun Signal. 2024 Jan 25;22(1):68. doi: 10.1186/s12964-023-01421-9. Cell Commun Signal. 2024. PMID: 38273295 Free PMC article. Review.
-
Intra-tumor ROS amplification by melatonin interferes in the apoptosis-autophagy-inflammation-EMT collusion in the breast tumor microenvironment.Heliyon. 2023 Dec 20;10(1):e23870. doi: 10.1016/j.heliyon.2023.e23870. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38226217 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
